Delivery Order SPE2DB24D2010-SPE2DB25FAACM
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,936.96 delivery order on July 23, 2025, for XYOSTED 75 mg/0.5 mL auto-injector units (0.5 mL). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 24, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's larger pharmaceutical supply...
- The Defense Logistics Agency (DLA) awarded a $1,629.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector pharmaceutical supplies, with an ultimate completion date of July 21, 2025. This non-set-aside competitively awarded contract represents a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle...
- The Defense Logistics Agency awarded a $1,358.05 delivery order to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 mL auto-injector units. This non-set-aside contract is classified as a firm fixed price delivery order with an ultimate completion date of August 28, 2025, and was awarded on August 27, 2025. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $2,716.10 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with an ultimate completion date of September 15, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is the vendor performing the work at its corporate office location in the same municipality. This delivery order is issued...
- The Defense Logistics Agency awarded a $1,270.28 firm fixed price delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with an ultimate completion date of July 28, 2025. This non-set-aside contract represents a single delivery order fulfillment under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The delivery...
- The Defense Logistics Agency awarded a $1,436.03 delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Xyosted 75 mg/0.5 ml auto-injector units. The contract is a firm fixed-price delivery order with an ultimate completion date of June 2, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical procurement vendor specializing in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 16, 2025, for the supply of Xyosted 50 mg/0.5 mL auto-injector (testosterone replacement therapy) with a ceiling value of $2,172.88. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of July 17, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,149.65 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector units on September 5, 2025, with a completion date of September 8, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), an enterprise-wide pharmaceutical prime vendor vehicle valued at...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector pre-filled syringes valued at $1,716.22. This is a firm fixed price delivery order with an ultimate completion date of July 15, 2025, and represents a non-competitive set-aside award. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract, this delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $1,086.44 to AmerisourceBergen Drug Corp for the supply of Xyosted 75 mg/0.5 ml auto-injector units. The contract, awarded on August 15, 2025, with an ultimate completion date of August 18, 2025, represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. Performance will occur at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FAACMDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector supplies, valued at $1,006.78 under a firm fixed-price arrangement. The award, issued on June 30, 2025, with an ultimate completion date of July 1, 2025, represents a non-competitive delivery order. Performance will be executed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's DLA Troop Support Medical IDC enables the supply of a broad range of pharmaceutical products and medical supplies across multiple therapeutic domains to support Defense Health Agency operations and other government healthcare systems worldwide. This specific delivery order for XYOSTED—an injectable testosterone replacement therapy—reflects the vendor's role in supplying specialized pharmaceutical products to federal healthcare customers through the flexible IDC framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 6/30/25 |